1
|
Assolini JP, Carloto ACM, Bortoleti BTDS, Gonçalves MD, Tomiotto Pellissier F, Feuser PE, Cordeiro AP, Hermes de Araújo PH, Sayer C, Miranda Sapla MM, Pavanelli WR. Nanomedicine in leishmaniasis: A promising tool for diagnosis, treatment and prevention of disease - An update overview. Eur J Pharmacol 2022; 923:174934. [PMID: 35367420 DOI: 10.1016/j.ejphar.2022.174934] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 03/23/2022] [Accepted: 03/28/2022] [Indexed: 12/17/2022]
Abstract
Leishmaniasis is a neglected tropical disease that has a wide spectrum of clinical manifestations, ranging from visceral to cutaneous, with millions of new cases and thousands of deaths notified every year. The severity of the disease and its various clinical forms are determined by the species of the causative agent, Leishmania, as well as the host's immune response. Major challenges still exist in the diagnosis and treatment of leishmaniasis, and there is no vaccine available to prevent this disease in humans. Nanotechnology has emerged as a promising tool in a variety of fields. In this review, we highlight the main and most recent advances in nanomedicine to improve the diagnosis and treatment, as well as for the development of vaccines, for leishmaniasis. Nanomaterials are nanometric in size and can be produced by a variety of materials, including lipids, polymers, ceramics, and metals, with varying structures and morphologies. Nanotechnology can be used as biosensors to detect antibodies or antigens, thus improving the sensitivity and specificity of such immunological and molecular diagnostic tests. While in treatment, nanomaterials can act as drug carriers or, be used directly, to reduce any toxic effects of drug compounds to the host and to be more selective towards the parasite. Furthermore, preclinical studies show that different nanomaterials can carry different Leishmania antigens, or even act as adjuvants to improve a Th1 immune response in an attempt to produce an effective vaccine.
Collapse
Affiliation(s)
- João Paulo Assolini
- Department of Pathological Sciences, Center of Biological Sciences, State University of Londrina, PR, Brazil; Universidade Alto Vale do Rio Peixe, Caçador, SC, Brazil.
| | | | | | | | | | - Paulo Emilio Feuser
- Department of Chemical Engineering and Food Engineering, Federal University of Santa Catarina, SC, Brazil
| | - Arthur Poester Cordeiro
- Department of Chemical Engineering and Food Engineering, Federal University of Santa Catarina, SC, Brazil
| | | | - Claudia Sayer
- Department of Chemical Engineering and Food Engineering, Federal University of Santa Catarina, SC, Brazil
| | | | - Wander Rogério Pavanelli
- Department of Pathological Sciences, Center of Biological Sciences, State University of Londrina, PR, Brazil.
| |
Collapse
|
2
|
Ferreira MA, de Almeida Júnior RF, Onofre TS, Casadei BR, Farias KJS, Severino P, de Oliveira Franco CF, Raffin FN, de Lima e Moura TFA, de Melo Barbosa R. Annatto Oil Loaded Nanostructured Lipid Carriers: A Potential New Treatment for Cutaneous Leishmaniasis. Pharmaceutics 2021; 13:1912. [PMID: 34834327 PMCID: PMC8618414 DOI: 10.3390/pharmaceutics13111912] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 10/14/2021] [Accepted: 10/25/2021] [Indexed: 11/18/2022] Open
Abstract
Annatto (Bixa orellana L.) is extensively used as food pigment worldwide. Recently, several studies have found it to have healing and antioxidant properties, as well as effective action against leishmaniasis. Therefore, the purpose of this study was to incorporate the oil obtained from annatto seeds into a nanostructured lipid carrier (NLC) and evaluate its physicochemical properties and biological activity against Leishmania major. Nanoparticles were prepared by the fusion-emulsification and ultrasonication method, with the components Synperonic™ PE (PL) as the surfactant, cetyl palmitate (CP) or myristyl myristate (MM) as solid lipids, annatto oil (AO) (2% and 4%, w/w) as liquid lipid and active ingredient, and ultra-pure water. Physicochemical and biological characterizations were carried out to describe the NLCs, including particle size, polydispersity index (PDI), and zeta potential (ZP) by dynamic light scattering (DLS), encapsulation efficiency (EE%), thermal behavior, X-ray diffraction (XRD), transmission electron microscopy (TEM), Electron Paramagnetic Resonance (EPR), cytotoxicity on BALB/c 3T3 fibroblasts and immortalized human keratinocyte cells, and anti-leishmaniasis activity in vitro. Nanoparticles presented an average diameter of ~200 nm (confirmed by TEM results), a PDI of less than 0.30, ZP between -12.6 and -31.2 mV, and more than 50% of AO encapsulated in NLCs. Thermal analyses demonstrated that the systems were stable at high temperatures with a decrease in crystalline structure due to the presence of AOs (confirmed by XRD). In vitro, the anti-leishmania test displayed good activity in encapsulating AO against L. major. The results indicate that the oily fraction of Bixa orellana L. in NLC systems should be evaluated as a potential therapeutic agent against leishmaniasis.
Collapse
Affiliation(s)
- Marianna Araújo Ferreira
- Laboratory of Drug Development, Department of Pharmacy, Federal University of Rio Grande do Norte, Natal 59012-570, Brazil; (M.A.F.); (F.N.R.)
| | | | - Thiago Souza Onofre
- Biochemistry and Molecular Biology Department, Federal University of Viçosa (UFV), Viçosa 36570-900, Brazil;
| | - Bruna Renata Casadei
- Institute of Physics, University of São Paulo, USP, São Paulo 05508-090, Brazil;
| | | | - Patricia Severino
- Institute of Technology and Research (ITP), Aracaju 49010-390, Brazil;
| | | | - Fernanda Nervo Raffin
- Laboratory of Drug Development, Department of Pharmacy, Federal University of Rio Grande do Norte, Natal 59012-570, Brazil; (M.A.F.); (F.N.R.)
| | | | - Raquel de Melo Barbosa
- Laboratory of Drug Development, Department of Pharmacy, Federal University of Rio Grande do Norte, Natal 59012-570, Brazil; (M.A.F.); (F.N.R.)
| |
Collapse
|
3
|
Briones Nieva CA, Cid AG, Romero AI, García-Bustos MF, Villegas M, Bermúdez JM. An appraisal of the scientific current situation and new perspectives in the treatment of cutaneous leishmaniasis. Acta Trop 2021; 221:105988. [PMID: 34058160 DOI: 10.1016/j.actatropica.2021.105988] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Revised: 05/23/2021] [Accepted: 05/24/2021] [Indexed: 12/18/2022]
Abstract
Leishmaniasis is a Neglected Tropical Diseases caused by protozoan parasites of the genus Leishmania. It is a major health problem in many tropical and subtropical regions of the world and can produce three different clinical manifestations, among which cutaneous leishmaniasis has a higher incidence in the world than the other clinical forms. There are no recognized and reliable means of chemoprophylaxis or vaccination against infections with different forms of leishmaniasis. In addition, chemotherapy, unfortunately, remains, in many respects, unsatisfactory. Therefore, there is a continuing and urgent need for new therapies against leishmaniasis that are safe and effective in inducing a long-term cure. This review summarizes the latest advances in currently available treatments and improvements in the development of drug administration. In addition, an analysis of the in vivo assays was performed and the challenges facing promising strategies to treat CL are discussed. The treatment of leishmaniasis will most likely evolve into an approach that uses multiple therapies simultaneously to reduce the possibility of developing drug resistance. There is a continuous effort to discover new drugs to improve the treatment of leishmaniasis, but this is mainly at the level of individual researchers. Undoubtedly, more funding is needed in this area, as well as greater participation of the pharmaceutical industry to focus efforts on the development of chemotherapeutic agents and vaccines for this and other neglected tropical diseases.
Collapse
Affiliation(s)
- C A Briones Nieva
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta - Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, (4400) Salta, Argentina
| | - Alicia Graciela Cid
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta - Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, (4400) Salta, Argentina
| | - Analía Irma Romero
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta - Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, (4400) Salta, Argentina
| | - María Fernanda García-Bustos
- Instituto de Patología Experimental, Universidad Nacional de Salta - Consejo Nacional de Investigaciones Científicas y Técnicas, Salta, Argentina
| | - Mercedes Villegas
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta - Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, (4400) Salta, Argentina
| | - José María Bermúdez
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta - Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, (4400) Salta, Argentina.
| |
Collapse
|
4
|
Anderson O, Beckett J, Briggs CC, Natrass LA, Cranston CF, Wilkinson EJ, Owen JH, Mir Williams R, Loukaidis A, Bouillon ME, Pritchard D, Lahmann M, Baird MS, Denny PW. An investigation of the antileishmanial properties of semi-synthetic saponins. RSC Med Chem 2020; 11:833-842. [PMID: 33479679 PMCID: PMC7651632 DOI: 10.1039/d0md00123f] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 05/21/2020] [Indexed: 12/25/2022] Open
Abstract
Leishmaniasis is a neglected tropical disease caused by insect-vector borne protozoan parasites of the, Leishmania species. Whilst infection threatens and affects millions of the global poor, vaccines are absent and drug therapy limited. Extensive efforts have recently been made to discover new leads from small molecule synthetic compound libraries held by industry; however, the number of new chemical entities identified and entering development as anti-leishmanials has been very low. This has led to increased interest in the possibility of discovering naturally derived compounds with potent antileishmanial activity which may be developed towards clinical applications. Plant-derived triterpenoid and steroidal saponins have long been considered as anti-microbials and here we describe an investigation of a library of 137 natural (9) and semi-synthetic saponins (128) for activity against Leishmania mexicana, a causative agent of cutaneous leishmaniasis. The triterpenoid sapogenin, hederagenin, readily obtained in large quantities from Hedera helix (common ivy), was converted into a range of 128 derivatives. These semi-synthetic compounds, as well as saponins isolated from ivy, were examined with a phenotypic screening approach to identify potent and selective anti-leishmanial hits. This led to the identification of 12 compounds, including the natural saponin gypsogenin, demonstrating high potency (ED50 < 10.5 μM) against axenic L. mexicana amastigotes, the mammalian pathogenic form. One of these, hederagenin disuccinate, was sufficiently non-toxic to the macrophage host cell to facilitate further analyses, selectivity index (SI) > 10. Whilst this was not active in an infected cell model, the anti-leishmanial properties of hederagenin-derivatives have been demonstrated, and the possibility of improving the selectivity of natural hederagenin through chemical modification has been established.
Collapse
Affiliation(s)
- Orlagh Anderson
- Department of Biosciences and Centre for Global Infectious Diseases , Durham University , Stockton Road , Durham , DH1 3LE , UK . ; Tel: +44 (0)191 3343983
| | - Joseph Beckett
- Department of Biosciences and Centre for Global Infectious Diseases , Durham University , Stockton Road , Durham , DH1 3LE , UK . ; Tel: +44 (0)191 3343983
| | - Carla C Briggs
- Department of Biosciences and Centre for Global Infectious Diseases , Durham University , Stockton Road , Durham , DH1 3LE , UK . ; Tel: +44 (0)191 3343983
| | - Liam A Natrass
- Department of Biosciences and Centre for Global Infectious Diseases , Durham University , Stockton Road , Durham , DH1 3LE , UK . ; Tel: +44 (0)191 3343983
- Department of Chemistry and Centre for Global Infectious Diseases , Durham University , Stockton Road , Durham , DH1 3LE , UK
| | - Charles F Cranston
- Department of Biosciences and Centre for Global Infectious Diseases , Durham University , Stockton Road , Durham , DH1 3LE , UK . ; Tel: +44 (0)191 3343983
| | - Elizabeth J Wilkinson
- Department of Chemistry , School of Natural Science , Bangor University , Gwynedd LL57 2UW , UK
| | - Jack H Owen
- Department of Chemistry , School of Natural Science , Bangor University , Gwynedd LL57 2UW , UK
| | - Rhodri Mir Williams
- Department of Chemistry , School of Natural Science , Bangor University , Gwynedd LL57 2UW , UK
| | - Angelos Loukaidis
- Department of Chemistry , School of Natural Science , Bangor University , Gwynedd LL57 2UW , UK
| | - Marc E Bouillon
- Department of Chemistry , School of Natural Science , Bangor University , Gwynedd LL57 2UW , UK
| | - Deiniol Pritchard
- Naturiol Bangor Ltd , Alun Roberts Building , Bangor University , Gwynedd LL57 2UW , UK
| | - Martina Lahmann
- Department of Chemistry , School of Natural Science , Bangor University , Gwynedd LL57 2UW , UK
| | - Mark S Baird
- Naturiol Bangor Ltd , Alun Roberts Building , Bangor University , Gwynedd LL57 2UW , UK
| | - Paul W Denny
- Department of Biosciences and Centre for Global Infectious Diseases , Durham University , Stockton Road , Durham , DH1 3LE , UK . ; Tel: +44 (0)191 3343983
| |
Collapse
|